BioSpace News Archive

Debiopharm, a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, announced data releases on two investigational products, namely Debio 0123, and Debio 0228/0328, at the 2023 American Society of Clinical Oncology meeting in Chicago, Illinois.

Mediso Medical Imaging Systems recently installed a state-of-the-art 7T MRI at the University of Milano-Bicocca.

The National Comprehensive Cancer Network® announced the signing of a Memo of Understanding with Vietnam National Cancer Hospital and the Vietnam Cancer Association to work together to improve standards for cancer care throughout the country.

Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announced today that it has signed an exclusive licensing agreement with Eikon Therapeutics.

Revvity, Inc. (NYSE: RVTY), announced today that its EUROIMMUN business has launched the UNIQO 160 (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics.

Cassava Sciences, Inc., a clinical-stage biotechnology company focused on Alzheimer’s disease, announced that its management has been invited to present at the Jefferies Global Healthcare Conference in New York City.

VolitionRx Limited, a multi-national epigenetics company, announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock at a public offering price of $1.27 per share.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the results of a post-hoc, pooled analysis of the Phase 2 AURA-LV (NCT02141672) and Phase 3 AURORA 1 (NCT03021499) studies, which found that LUPKYNIS® with mycophenolate mofetil (MMF) and low-dose steroids resulted in earlier and greater reductions in proteinuria in lupus nephritis (LN) patients with high proteinuria across biopsy classes, races, and ethnicities.

Ezra, the healthcare AI startup transforming early cancer detection through full body MRI screening, announced today that its newest proprietary Artificial Intelligence, Ezra Flash, has received 510(k) clearance by the U.S. Food and Drug Administration (FDA).

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam.